Key Points – At a Glance
The MVista® Histoplasma Antigen Quantitative EIA  (MVista® Histo Ag EIA, test code 310), has changed how we diagnose and monitor treatment of histoplasmosis. For initial testing, urine is the sample of choice. When urine is tested, the MVista® Histo Ag EIA is highly sensitive (92%) and specific (99%) . MVista® Histo Ag EIA is validated for antigen detection in urine, serum, plasma, BAL fluid and CSF, an advantage compared to Histoplasma antigen test offered elsewhere.
Testing serum is useful for diagnosis of cases with negative results in urine especially in patients with acute pulmonary histoplasmosis, where up about half of cases may have been missed if only urine was tested . Another advantage of testing serum is that the concentration in serum is usually quantifiable if the sample result in urine is above the limit of quantification (ALQ). In such cases monitoring clearance from serum is recommended until the urine concentration drops into the quantifiable range.
The MVista® Histo Ag EIA is useful for guiding treatment  and diagnosing relapse early , important characteristics lacking in the other commercial Histoplasma antigen detection assays.
The improved MVista® Histoplasma Ag EIA retains the advantages of the older assay: unequaled accuracy, quick turnaround time, and availability of consultants experienced with diagnosis and management of histoplasmosis.
The improved MVista® Histo Ag EIA has undergone rigorous validation testing, and results are impressive. As expected, cross-reactivity occurs in 90% of specimens from patients with blastomycosis  and 60% with coccidioidomycosis .
At MiraVista, quality-control goes beyond test development and validation. There are many layers of safeguards built into the daily testing protocols to ensure that results are highly accurate. Free consultation is provided for questions related to use of these tests for diagnosis and patient management: call: 888-841-8387 or email firstname.lastname@example.org.